Targeting P13K / mTOR Signaling in Cancer
Hyatt Regency San Francisco
5 Embarcadero Center
San Francisco, California


   American Association for Cancer Research

   Upcoming Conferences at the Forefront of Cancer Research

   February 24-27, 2011

   Targeting P13K/mTOR Signaling in Cancer

   Chairpersons: Lewis C. Cantley, Funda Meric-Burnstam, and David M.
   Sabatini San Francisco, CA

   Please visit often for additional
   conferences and program updates.

Schedule of Presentations:

Thursday, February 24, 2011
19:00:00 Keynote Session Lewis C Cantley
19:30:00 Title to be announced José Baselga
20:00:00 Networking Reception
Friday, February 25, 2011
07:00:00 Continental Breakfast
08:00:00 Session 1 | PI3K/mTOR Signaling Lewis C Cantley
08:30:00 PI3-Kinase and cancer cell metabolism Lewis C Cantley
09:00:00 Direct and indirect actions of PI3K in cancer Bart Vanhaesebroeck
09:30:00 Growth control by the mTOR pathway David M Sabatini
10:00:00 The TSC-mTOR pathway regulates tumor cell metabolism downstream of PI3K Brendan Manning
10:10:00 Short talk from proffered paper
10:15:00 Break
10:45:00 Session 2 | PI3K Pathway Aberrations in Human Cancer Gordon Mills
11:00:00 Strategies for targeting the PI3K pathway when employing combination therapies Jeffrey Adam Engelman
11:15:00 Panning for PI3K pathway gold in the cancer genome: A tale of modern 49ers Ramon E Parsons
11:30:00 PI3K signaling and therapeutic response in gliomas Eric C Holland
11:45:00 Signaling feedback upon inhibition of PI3K: Implications for clinical trials Carlos L. Arteaga
11:55:00 Short talk from proffered paper
13:00:00 Poster Session A and Lunch
16:00:00 Session 3 | Development of Novel PI3K/mTOR Pathway Inhibitors David M Sabatini
16:15:00 Chemical genetic dissection of growth factor kinase signaling K M Shokat
16:30:00 The development of PI3K and mTOR inhibitors in cancer William R Sellers
16:45:00 Targeting the PI3K-mTOR pathway with cancer therapeutics: More or less Robert T. Abraham
17:00:00 GSK2126458: A potent inhibitor of PI3K and mTOR Richard WOOSTER
17:15:00 Short talk from proffered paper
18:15:00 Evening off | Dinner on own
Saturday, February 26, 2011
07:00:00 Continental Breakfast
08:00:00 Session 4 | Targeting mTOR Funda Meric-Bernstam
08:15:00 Predictors and pharmacodynamic markers of rapamycin response Funda Meric-Bernstam
08:30:00 Translating the PI3K/mTOR pathway and translational control to radiation therapy Robert J Schneider
08:45:00 Pharmacology of AZD8055, a selective mTOR kinase inhibitor Sylvie M. Guichard
09:00:00 Title to be announced Neal Rosen
10:00:00 Break
10:30:00 Session 5 | Late-Breaking Research / Hot Topics Lewis C Cantley, David M Sabatini
12:00:00 Lunch on own
14:00:00 Session 6 | PI3K/mTOR Signaling
14:15:00 Title to be announced
14:30:00 mTORC1 regulation by TSC2 Cheryl Lyn Walker
14:45:00 The phosphorylation tightrope: Balancing kinase and phosphatase activities in cancer Alexandra C Newton
15:00:00 Targeting PI3K isoforms in cancer Jean J Zhao
15:15:00 Pharmacogenetic targeting of the translational machinery downstream of oncogenic mTOR signaling Davide Ruggero
16:30:00 Dinner on own
19:30:00 Poster Session B | Reception
Sunday, February 27, 2011
07:00:00 Continental Breakfast
08:00:00 Session 7 | Novel PI3K/mTOR Pathway Inhibitors in Clinical Trials I Funda Meric-Bernstam
08:15:00 Molecular marker-based clinical trial designs to target the PI3K pathway Ana Gonzalez-Angulo
08:30:00 Overcoming challenges to targeting the PI3K pathway in cancer Gordon Mills
09:00:00 Clinical development of MK-2206: A potent oral allosteric AKT inhibitor Li Yan
09:30:00 Break
10:00:00 Session 8 | Novel PI3K/mTOR Pathway Inhibitors in Clinical Trials II Funda Meric-Bernstam
10:15:00 Targeting the PI3K/AKT/mTOR pathway in the clinic: Early results from the PREDICT program Razelle Kurzrock
10:30:00 Title to be announced Mark R Lackner
10:45:00 Title to be announced Joanne J. Lager
11:00:00 Short talk from proffered paper
11:50:00 Departure
3D Tissue Models
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.